TG Therapeutics director gifts 6,050 shares

Q: What insider transactions did TGTX director Laurence N. Charney report?

Laurence N. Charney reported three bona fide gifts of TG Therapeutics Common Stock, totaling 6,050 shares, dated August 6–7, 2026. All shares were transferred at $0.00 per share to a 501(c)(3) institution.

Q: How many TG Therapeutics (TGTX) shares were gifted on each date?

Across three transactions, Charney gifted 5,100 shares of TG Therapeutics Common Stock on August 6, 2026, and two additional gifts of 500 shares and 450 shares on August 7, 2026, for a total of 6,050 shares.

Q: Does Laurence N. Charney retain any interest in the gifted TGTX shares?

According to a footnote, Charney does not retain any beneficial ownership or pecuniary interest in the TG Therapeutics Common Stock gifted to the 501(c)(3) institution. This applies to all 6,050 shares reported as bona fide gifts.

Q: Were these TGTX gifts made under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not marked, and the transactions are reported as bona fide gifts of Common Stock. The report does not characterize them as trades executed under a pre-arranged Rule 10b5-1 trading plan.

Q: What type of security was involved in Laurence N. Charney's TGTX Form 4?

All reported transactions involve TG Therapeutics Common Stock as non-derivative securities. A footnote adds that remaining holdings include shares of restricted Common Stock, which vest over various time periods, though specific remaining share counts are not detailed here.

TG Therapeutics director Laurence N. Charney reported three bona fide gifts of Common Stock totaling 6,050 shares on August 6–7, 2026.

Accepted by SEC EDGAR 08/07/2026 - 05:00 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

TG Therapeutics director Laurence N. Charney reported three bona fide gifts of Common Stock totaling 6,050 shares on August 6–7, 2026. The shares were transferred at $0.00 per share to a 501(c)(3) institution, and he retains no beneficial ownership or pecuniary interest in the gifted stock. Remaining holdings are noted as including restricted Common Stock that vests over time.

Insider Trade Summary

6,050 shares gifted

Gift 3 txns

Insider Charney Laurence N

Role Director

Type	Security	Shares	Price	Value
Gift	Common Stock ^{F1, F2}	500	$0.00	$0.00
Gift	Common Stock ^{F1, F2}	450	$0.00	$0.00
Gift	Common Stock ^{F1, F2}	5,100	$0.00	$0.00

Holdings After Transaction: Common Stock — 173,640 shares (Direct)

Holdings Before and After: Common Stock, 179,690 to 173,640 shares (Direct)

Footnotes (2)

F1. 1. Represents a bona fide gift by the Reporting Person to a 501(c)(3) institution. The Reporting Person does not retain any beneficial ownership or pecuniary interest over the shares of the Company's Common Stock after effecting the transaction.
F2. 2. Includes shares of restricted Common Stock, which vest over various time periods.

Key Figures

Total shares gifted: 6050 shares Shares gifted on 2026-08-06: 5100 shares First gift on 2026-08-07: 500 shares +2 more

5 metrics

Total shares gifted 6050 shares Aggregate bona fide gifts of Common Stock on August 6–7, 2026

Shares gifted on 2026-08-06 5100 shares Bona fide gift of Common Stock on August 6, 2026

First gift on 2026-08-07 500 shares Bona fide gift of Common Stock on August 7, 2026

Second gift on 2026-08-07 450 shares Additional bona fide gift of Common Stock on August 7, 2026

Gift price per share $0.0000 Price per share for all reported bona fide gifts

Key Terms

bona fide gift, 501(c)(3) institution, restricted Common Stock

3 terms

bona fide gift financial

"transaction code "G" is described as a bona fide gift transfer"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

501(c)(3) institution regulatory

"bona fide gift by the Reporting Person to a 501(c)(3) institution"

restricted Common Stock financial

"Includes shares of restricted Common Stock, which vest over various time periods"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TGTX director Laurence N. Charney report?

Laurence N. Charney reported three bona fide gifts of TG Therapeutics Common Stock, totaling 6,050 shares, dated August 6–7, 2026. All shares were transferred at $0.00 per share to a 501(c)(3) institution.

How many TG Therapeutics (TGTX) shares were gifted on each date?

Across three transactions, Charney gifted 5,100 shares of TG Therapeutics Common Stock on August 6, 2026, and two additional gifts of 500 shares and 450 shares on August 7, 2026, for a total of 6,050 shares.

Who received the gifted TG Therapeutics (TGTX) shares from Laurence N. Charney?

A footnote states that the reported transactions represent bona fide gifts by Laurence N. Charney to a 501(c)(3) institution. He does not retain any beneficial ownership or pecuniary interest in the 6,050 gifted shares after these transfers.

Does Laurence N. Charney retain any interest in the gifted TGTX shares?

According to a footnote, Charney does not retain any beneficial ownership or pecuniary interest in the TG Therapeutics Common Stock gifted to the 501(c)(3) institution. This applies to all 6,050 shares reported as bona fide gifts.

Were these TGTX gifts made under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is not marked, and the transactions are reported as bona fide gifts of Common Stock. The report does not characterize them as trades executed under a pre-arranged Rule 10b5-1 trading plan.

What type of security was involved in Laurence N. Charney's TGTX Form 4?

All reported transactions involve TG Therapeutics Common Stock as non-derivative securities. A footnote adds that remaining holdings include shares of restricted Common Stock, which vest over various time periods, though specific remaining share counts are not detailed here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Charney Laurence N

(Last)

(First)

(Middle)

3020 CARRINGTON MILL BLVD, SUITE 475

(Street)

MORRISVILLE

NORTH CAROLINA

27560

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TG THERAPEUTICS, INC. [ TGTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/06/2026		G		5,100⁽¹⁾	D	$0	174,590⁽²⁾	D
Common Stock	08/07/2026		G		500⁽¹⁾	D	$0	174,090⁽²⁾	D
Common Stock	08/07/2026		G		450⁽¹⁾	D	$0	173,640⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. 1. Represents a bona fide gift by the Reporting Person to a 501(c)(3) institution. The Reporting Person does not retain any beneficial ownership or pecuniary interest over the shares of the Company's Common Stock after effecting the transaction.

2. 2. Includes shares of restricted Common Stock, which vest over various time periods.

	/s/ Laurence N. Charney	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR